Amyloidosis treatment discontinued from clinical trials
10 June 2019 | By European Pharmaceutical Review
A treatment for amyloidosis has been pulled from clinical trials after failing to reach endpoints.
List view / Grid view
Clinical Development
FDA approves first gene therapy for paediatric spinal muscular atrophy
29 May 2019 | By Victoria Rees (European Pharmaceutical Review)
The FDA has given approval to AveXis for the first treatment of paediatric spinal muscular atrophy (SMA).
Developing easy-to-swallow medicine for children
20 March 2019 | By Iqra Farooq (European Pharmaceutical Review)
A study has revealed an in vitro method that could screen various compounds, identifying ones that would make swallowing medicine easier...
Top novel drug approvals: February 2019
14 March 2019 | By Iqra Farooq
Cablivi and Egaten were the two top novel drugs approved last month, with a focus on parasitic infestation and the rare disorder, aTTP...
Statins might be linked to increased risk of diabetes
6 March 2019 | By European Pharmaceutical Review
Researchers have identified a possible association between use of statins and developing type 2 diabetes after following patients for 15 years...
Pharma drug delivery market worth $1,694.7 billion by 2023
4 March 2019 | By Iqra Farooq (European Pharmaceutical Review)
The pharmaceutical drug delivery market could reach $1,694.7 billion by 2023, increasing at a CAGR of 6.4 percent during the period...
Six new licensing deals for drug and gene therapy development firm
1 March 2019 | By European Pharmaceutical Review
Oxford Genetics has won six new licensing deals for its scalable drug and gene therapy manufacturing in the synthetic biology sector...
Darolutamide NDA to treat non-metastatic castration-resistant prostate cancer
27 February 2019 | By Iqra Farooq (European Pharmaceutical Review)
A New Drug Application has been made to the US Food and Drug Administration for the drug darolutamide to treat non-metastatic prostate cancer...
Expansion of the global antibiotics market size
26 February 2019 | By European Pharmaceutical Review
The global antibiotics market is set to increase at a CAGR of 4 percent to $62.06 billion, due to the rising prevalence of infectious diseases...
Whitepaper: Analytical criteria in bacterial endotoxin testing using LAL and rFC
21 February 2019 | By Hyglos-bioMerieux
This article covers the analytical criteria that apply to Bacterial Endotoxin Testing (BET) using Limulus Amebocyte Lysate (LAL) or recombinant Horseshoe crab Factor C (rFC) for the bioactivity determination of endotoxin in aqueous solutions, such as pharmaceuticals and medical device extracts. It explains the importance of these criteria for accurate…
‘Smart drug’ shows promise for metastatic triple-negative breast cancer
21 February 2019 | By European Pharmaceutical Review
A study has shown that a 'smart drug' that delivers a toxic payload directly to tumour cells could be a possible treatment for breast cancer...
Structural barriers biggest reason for low participation in clinical trials
20 February 2019 | By European Pharmaceutical Review
A study has shown how structural barriers are one of the main reasons why clinical trials often do not meet their enrolment targets...
Inadequate FDA oversight concerning fentanyl prescriptions
19 February 2019 | By European Pharmaceutical Review
A study has found that the FDA failed to design and implement an effective monitoring program for Transmucosal Immediate-Release Fentanyls...
Oral antifungals used to treat yeast infections could lead to miscarriage
19 February 2019 | By European Pharmaceutical Review
Researchers have found that fluconazole used to treat yeast infections in pregnant women could cause a higher risk of miscarriage...
Biotech firm awarded for approach to drug development
18 February 2019 | By European Pharmaceutical Review
A UK based biotech firm has been awarded a grant to develop a treatment for osteoarthritis, after promising results from a Phase I trial...
Follow: